✦ LIBER ✦

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

✍ Scribed by Dirk Strumberg, Beate Schultheis, M. E. Scheulen, R. A. Hilger, J. Krauss, N. Marschner, F. Lordick, F. Bach, D. Reuter, L. Edler, K. Mross

Book ID: 113064478
Publisher: Springer US
Year: 2010
Tongue: English
Weight: 144 KB
Volume: 30
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-010-9619-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

732 POSTER Phase I clinical study of the

732 POSTER Phase I clinical study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody (Nimotuzumab) in combination with chemotherapy in patients with locally-advanced breast cancer. Preliminary results

✍ J. Soriano; N. Batista; M. Lima; R. Rodríguez; M.V. López; A. Montenegro; M. Ram 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 83 KB

1247 Phase I study of nimotuzumab, a hum

1247 Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in Japanese patients with solid tumors

✍ N. Boku; K. Yamazaki; A. Fukutomi; T. Takahashi; N. Yamamoto; M. Miyazaki; T. Sa 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Results of a phase I trial of the humani

Results of a phase I trial of the humanized anti epidermal growth factor receptor (EGFr) monoclonal antibody emd 72000 in patients with EGFr expressing solid tumors

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 139 KB

A phase I study evaluating the role of t

A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer

✍ J. P. Arnoletti; A. Frolov; M. Eloubeidi; K. Keene; J. Posey; T. Wood; Edward Gr 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 369 KB

ABX-EGF, a fully human anti-epidermal gr

ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFr) monoclonal antibody: phase II clinical trial in renal cell cancer (RCC)

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 139 KB

A phase II study of capecitabine plus ge

A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer

✍ Hong Suk Song; Young Rok Do; Heung Moon Chang; Min Hee Ryu; Kyung Hee Lee; Yeul 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 271 KB